Sugi Predict

Sugi Predict / Compounds / SCHEMBL16037403

SCHEMBL16037403

SCHEMBL16037403

Cn1nc(Cl)cc(N2CCOCC2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH3A1 P30838 1/20 0.41
▸ ALDH1A3 P47895 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ RAF1 P04049 5/20 0.40
▸ BRAF P15056 5/20 0.40
▸ TP53 P04637 1/20 0.40
▸ PRKDC P78527 2/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26132490 0.84 CYP3A4 (0.36) ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2
SCHEMBL16094583 0.80 RAF1 (0.43) ALDH1A1MAPTRAF1BRAFPRKDC
SCHEMBL16095009 0.80 RAF1 (0.41) ALDH1A1CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL26131655 0.78 ALDH3A1 (0.38) ALDH3A1ALDH1A3ALDH1A1CYP3A4GAA
SCHEMBL26129418 0.78 ALDH1A1 (0.41) ALDH1A1RAF1BRAFHSD17B10
SCHEMBL16094298 0.77 RAF1 (0.43) RAF1BRAF
SCHEMBL16094295 0.77 RAF1 (0.43) RAF1BRAF
SCHEMBL16094776 0.77 RAF1 (0.43) RAF1BRAF
SCHEMBL26132259 0.76 KMT2A (0.43) ALDH1A1GAAMAPTSMN1; SMN2KMT2A
SCHEMBL26131236 0.76 ALDH1A1 (0.40) ALDH3A1ALDH1A3ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250248998-A1 LRRK2 Inhibitors Brenig Therapeutics, Inc. 2025-08-07 — — US disclosed
EP-4504722-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2025-02-12 — — EP disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
WO-2023196720-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2023-10-12 — — WO disclosed
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
CN-105143209-A Biaryl amide compounds as kinase inhibitors NOVARTIS AG 2015-12-09 — — CN disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250248998-A1 LRRK2 Inhibitors LRRK2, PARK7, PINK1 ALDH3A1 3228/4885ALDH1A3 2647/4885ALDH1A1 2670/4885
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS ALDH3A1 1401/4885ALDH1A3 2839/4885ALDH1A1 1592/4885
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF ALDH3A1 1443/4885ALDH1A3 1542/4885ALDH1A1 2049/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS ALDH3A1 1401/4885ALDH1A3 2839/4885ALDH1A1 1592/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS ALDH3A1 1401/4885ALDH1A3 2839/4885ALDH1A1 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.